Source:http://linkedlifedata.com/resource/pubmed/id/14712288
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2004-2-24
|
| pubmed:abstractText |
NZB mice develop an age-related malignant expansion of a subset of B cells, B-1 cells, with autocrine production of IL-10. IL-10, a pleiotropic cytokine with anti-inflammatory properties, is a potent growth and survival factor for malignant B cells. To further examine the in vivo requirement for IL-10 in the development and expansion of malignant B-1 clones in NZB mice, we developed a strain of homozygous IL-10 knockout (KO) mice on an NZB background. The NZB IL-10 KO mice develop peritoneal B-1 cells with approximately the same frequency as heterozygous and wild-type littermates. In contrast, the development of malignant B-1 cells in the peripheral blood and spleen, observed in wild-type NZB, rarely occurred in the NZB IL-10 KO. Phenotypic analysis of surface marker expression in splenic B cells indicated that, in contrast to the NZB with malignant B-1 splenic lymphoma, the surface marker expression of NZB IL-10 KO splenic B cells indicated that the majority of the B cells were typical B-2 cells. In the absence of IL-10, spontaneously activated B cells and antiapoptotic gene expression were reduced and lymphoma incidence was decreased. These results indicate that IL-10 is a critical factor for the progression of this B-cell malignant disease.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0887-6924
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
18
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
597-606
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:14712288-Animals,
pubmed-meshheading:14712288-B-Lymphocytes,
pubmed-meshheading:14712288-Crosses, Genetic,
pubmed-meshheading:14712288-Disease Progression,
pubmed-meshheading:14712288-Female,
pubmed-meshheading:14712288-Intercellular Adhesion Molecule-1,
pubmed-meshheading:14712288-Interleukin-10,
pubmed-meshheading:14712288-Lymphocyte Activation,
pubmed-meshheading:14712288-Lymphoma, B-Cell,
pubmed-meshheading:14712288-Male,
pubmed-meshheading:14712288-Mice,
pubmed-meshheading:14712288-Mice, Inbred C57BL,
pubmed-meshheading:14712288-Mice, Inbred NZB,
pubmed-meshheading:14712288-Mice, Knockout,
pubmed-meshheading:14712288-Mice, Transgenic,
pubmed-meshheading:14712288-RNA, Messenger,
pubmed-meshheading:14712288-Spleen,
pubmed-meshheading:14712288-Splenic Neoplasms
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma.
|
| pubmed:affiliation |
Department of Pathology, New Jersey Medical School, Newark, NJ, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|